Results 181 to 190 of about 45,359 (314)

Association of Biliary Source <i>Klebsiella pneumoniae</i> Pyogenic Liver Abscess With Colon Adenocarcinoma: A Case Report. [PDF]

Case Rep Gastrointest Med
Shin D, Kandhi S, Sosa F, Zacharia G, Patel H.   +4 more
europepmc   +1 more source

Defining the tumor microenvironment of non‐small cell lung cancer

Immunology &Cell Biology, EarlyView.
The tumor microenvironment (TME) in non‐small cell lung cancer is highly heterogeneous, both at a patient level and tumor microenvironment resolution. Defining the tumor microenvironment from patient‐responders and non‐responders will aid in the development of targeted therapeutics specific for each individual patient.
Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe   +5 more
wiley   +1 more source

Outcomes Following Antifungal Treatment for <i>Candida</i> Growth in Bile Cultures Collected During Endoscopic Retrograde Cholangiopancreatography. [PDF]

J Fungi (Basel)
Charpentier G, Smith KA, Slaven JE, Emeli TO, Susler RG, Chehab H, Gromski MA, Khan H, Gupta SK, Barros N.   +9 more
europepmc   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

Early-life body size and risk of developing biliary tract cancers. [PDF]

Cancer
Bhattacharjee PS, Baker JL, Pfeiffer RM, Jackson SS, Aarestrup J, Koshiol J.   +5 more
europepmc   +1 more source

Five Advances in Benign Pancreatic Surgery in the Last 50 Years

World Journal of Surgery, EarlyView.
Stephan B. Dreyer, Rowan W. Parks
wiley   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Real-world evidence on second line chemotherapy in advanced biliary tract carcinoma refractory to gemcitabine and oxaliplatin (GemOx). [PDF]

BMC Cancer
Lagenfelt H, Blomstrand H, Gränsmark E, Elander NO.   +3 more
europepmc   +1 more source

Immune Evasion of Helicobacter pylori and Extra‐Gastric Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Helicobacter pylori (H. pylori) is a group 1 gastric carcinogen that plays a significant role in extra‐gastric digestive system cancers. H. pylori disrupts host cell homeostasis through expression of virulence factors leading to immune evasion as well as persistent gastric mucosal colonization. H. pylori infection has been shown to play a role
Evren Doruk Engin, Ayse Basak Engin, Atilla Engin   +2 more
wiley   +1 more source

Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study. [PDF]

J Pharm Health Care Sci
Fukushi Y, Fujita K, Akamine Y, Igarashi H, Sasaki K, Fukuda K, Shibata H, Kikuchi M.   +7 more
europepmc   +1 more source